About the Company
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.
Employees
13
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ABIO News
ABIO ARCA biopharma, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted ...
ARCA biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Get 7 Days Free Sign In Sign In Topics ...
ABIO ARCA biopharma, Inc.
The chart has 1 X axis displaying Time. Data ranges from 2022-03-03 00:00:00 to 2023-03-03 00:00:00. The chart has 1 Y axis displaying values. Data ranges from -18.02 to 26.87.
ARCA biopharma, Inc. Common Stock (ABIO)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
ARCA biopharma, Inc.: ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted ...
ARCA biopharma, Inc. Common Stock (ABIO)
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...
Loading the latest forecasts...